| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(13)70240-7 |
| P698 | PubMed publication ID | 23810788 |
| P50 | author | George Wilding | Q5546267 |
| Richard Baird | Q42878560 | ||
| Susana Miranda | Q56450977 | ||
| Shahneen K Sandhu | Q60042780 | ||
| Carlo Toniatti | Q86902984 | ||
| Khin Thway | Q86996040 | ||
| P2093 | author name string | Johann S de Bono | |
| Robert M Wenham | |||
| Aurelius Omlin | |||
| Ruth Riisnaes | |||
| Stan B Kaye | |||
| Victor Moreno | |||
| Robert Iannone | |||
| Manash Chatterjee | |||
| William R Schelman | |||
| Heidrun Gevensleben | |||
| Martin Forster | |||
| Linda Sun | |||
| Christopher L Carpenter | |||
| Lucy Hylands | |||
| John Loughney | |||
| Nathan Kreischer | |||
| P2860 | cites work | Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer | Q24302687 |
| Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro | Q24615499 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. | Q27851580 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Germline mutations in RAD51D confer susceptibility to ovarian cancer | Q28245028 | ||
| Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer | Q28287454 | ||
| The mutational landscape of lethal castration-resistant prostate cancer | Q29614634 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 | ||
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group | Q33566395 | ||
| Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. | Q34973214 | ||
| FANCF methylation contributes to chemoselectivity in ovarian cancer | Q35142957 | ||
| PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma | Q35871546 | ||
| Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors | Q36042091 | ||
| A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer | Q36204215 | ||
| Dual roles of PARP-1 promote cancer growth and progression | Q36460391 | ||
| A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer | Q37081107 | ||
| Mutations in CHEK2 associated with prostate cancer risk | Q37219438 | ||
| Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic | Q37826009 | ||
| The DNA damage response and cancer therapy | Q37977004 | ||
| Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity | Q38400993 | ||
| Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval | Q39712677 | ||
| Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors | Q39782128 | ||
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study | Q44846367 | ||
| Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). | Q47936662 | ||
| NBS1 is a prostate cancer susceptibility gene. | Q51029363 | ||
| Dose-finding in phase I clinical trials based on toxicity probability intervals. | Q51907391 | ||
| Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. | Q52623792 | ||
| Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer | Q56807699 | ||
| Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors | Q57693963 | ||
| Accelerated titration designs for phase I clinical trials in oncology | Q73598986 | ||
| P433 | issue | 9 | |
| P921 | main subject | phase I clinical trial | Q5452194 |
| P304 | page(s) | 882-892 | |
| P577 | publication date | 2013-06-28 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial | |
| P478 | volume | 14 |
| Q33618910 | "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors |
| Q91241124 | 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer |
| Q38780396 | A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy. |
| Q92890485 | A decade of clinical development of PARP inhibitors in perspective |
| Q50127567 | A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer |
| Q33439527 | A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours |
| Q27302763 | A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An |
| Q57106332 | Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice? |
| Q36252996 | Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. |
| Q38206546 | Advances in the approach to novel drug clinical development for breast cancer |
| Q57108063 | Advances in the use of PARP inhibitor therapy for breast cancer |
| Q38553247 | An overview of early investigational therapies for chemoresistant ovarian cancer. |
| Q38631373 | An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. |
| Q35142718 | An update on PARP inhibitors for the treatment of cancer |
| Q38257125 | An update on PARP inhibitors--moving to the adjuvant setting |
| Q48110323 | Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer |
| Q38152942 | Appraising iniparib, the PARP inhibitor that never was--what must we learn? |
| Q33877435 | Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples. |
| Q50210067 | Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches |
| Q37605747 | BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different |
| Q40074639 | BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers |
| Q38644661 | BRCA mutation in ovarian cancer: testing, implications and treatment considerations |
| Q53495668 | BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping. |
| Q63884154 | BRCA2 and Other DDR Genes in Prostate Cancer |
| Q38746010 | BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer |
| Q26852274 | Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors |
| Q38893074 | Biology and Management of Patients With Triple-Negative Breast Cancer |
| Q47561562 | Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing |
| Q64054522 | CADM1 is a TWIST1-regulated suppressor of invasion and survival |
| Q28073246 | Chemoresistance and targeted therapies in ovarian and endometrial cancers |
| Q26863501 | Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising |
| Q38815964 | Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. |
| Q35592388 | Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft |
| Q38751236 | Current and emerging treatment options in the management of advanced ovarian cancer |
| Q33823472 | Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers |
| Q92697499 | Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer |
| Q47155297 | Current status of poly(ADP-ribose) polymerase inhibitors and future directions. |
| Q26739366 | Cytotoxic and targeted therapy for hereditary cancers |
| Q52659702 | DNA Damage Response in Prostate Cancer. |
| Q26829155 | DNA damage response and prostate cancer: defects, regulation and therapeutic implications |
| Q41527706 | DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial |
| Q37600799 | DNA repair in cancer: emerging targets for personalized therapy. |
| Q26768679 | DNA repair targeted therapy: The past or future of cancer treatment? |
| Q27853235 | DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer |
| Q92814129 | Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib |
| Q85398023 | Detection of ADP ribosylation in PARP-1 and bacterial toxins using a capillary-based western system |
| Q48172142 | Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients. |
| Q38844202 | Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy |
| Q34380368 | Development of synthetic lethality anticancer therapeutics |
| Q41783629 | Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors |
| Q89133950 | Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers |
| Q39455545 | Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors |
| Q36172457 | Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma |
| Q33584594 | Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia |
| Q36562360 | E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling |
| Q58565563 | Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial |
| Q54276736 | Elucidating the genomic landscape of breast cancer: how will this affect treatment? |
| Q26777310 | Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer |
| Q36854062 | Emerging therapeutic targets in metastatic progression: A focus on breast cancer |
| Q37158437 | Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy |
| Q61798290 | Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency |
| Q38943129 | Excessive Reactive Oxygen Species and Exotic DNA Lesions as an Exploitable Liability |
| Q38466329 | Exploiting replicative stress to treat cancer |
| Q37715826 | Functional assays for analysis of variants of uncertain significance in BRCA2. |
| Q89659606 | Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? |
| Q101237469 | Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer |
| Q26769604 | Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy |
| Q53787362 | Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. |
| Q38735426 | Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. |
| Q27006938 | Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers |
| Q34228853 | Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing |
| Q37581351 | Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. |
| Q47160372 | High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. |
| Q90284086 | How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors |
| Q47119281 | Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer |
| Q93355720 | Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia |
| Q37726508 | In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. |
| Q99248250 | Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma |
| Q48740484 | International Gynecologic Cancer Society (IGCS) 2016: Meeting report |
| Q38893354 | Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer |
| Q38726394 | Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. |
| Q59238251 | Made-to-measure medicine: BRCA and gynaecological cancer |
| Q89459806 | Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway |
| Q42398020 | Major milestones in translational oncology. |
| Q89471826 | MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC |
| Q48110433 | Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. |
| Q38151036 | Molecular pathology and prostate cancer therapeutics: from biology to bedside |
| Q34135434 | Molecular pathways: targeting ETS gene fusions in cancer |
| Q61796965 | NADP is an endogenous PARP inhibitor in DNA damage response and tumor suppression |
| Q38756892 | New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors |
| Q26741855 | New challenges for BRCA testing: a view from the diagnostic laboratory |
| Q37519943 | New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes |
| Q28082524 | New perspectives on targeted therapy in ovarian cancer |
| Q38949133 | New therapeutic perspectives in CCDC6 deficient lung cancer cells |
| Q49962911 | New therapeutic strategies to treat human cancers expressing mutant p53 proteins |
| Q26745614 | New treatment option for ovarian cancer: PARP inhibitors |
| Q34104143 | Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells |
| Q38744399 | Niraparib for the treatment of ovarian cancer |
| Q42820765 | Niraparib in ovarian cancer: results to date and clinical potential. |
| Q92857990 | Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial |
| Q93043588 | Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial |
| Q90730487 | Niraparib: A Review in Ovarian Cancer |
| Q37595954 | Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas |
| Q38198095 | Novel therapies, including enzastaurin, in the treatment of ovarian cancer |
| Q26851765 | Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition |
| Q41091405 | Nuclear PARP1 expression and its prognostic significance in breast cancer patients. |
| Q92421010 | Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial |
| Q91733148 | Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial |
| Q49710396 | Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells. |
| Q56240758 | Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation |
| Q92716047 | Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer |
| Q88195269 | Ovarian cancer |
| Q60950302 | Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment |
| Q64913988 | PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. |
| Q27027503 | PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies |
| Q26768661 | PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives |
| Q92164257 | PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca" |
| Q39328164 | PARP Inhibitors in Prostate Cancer |
| Q92257452 | PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development |
| Q37607283 | PARP Inhibitors in Reproductive System Cancers: Current Use and Developments |
| Q42517340 | PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer |
| Q89581160 | PARP and PARG inhibitors in cancer treatment |
| Q38225315 | PARP inhibition and synthetic lethality in ovarian cancer |
| Q48246094 | PARP inhibition in castration-resistant prostate cancer |
| Q38795712 | PARP inhibitors as antitumor agents: a patent update (2013-2015). |
| Q48164214 | PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. |
| Q28071345 | PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions |
| Q52623144 | PARP inhibitors for homologous recombination-deficient prostate cancer. |
| Q52585367 | PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. |
| Q36752061 | PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions |
| Q64279560 | PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms |
| Q38194324 | PARP inhibitors in ovarian cancer: current status and future promise |
| Q33605912 | PARP inhibitors in ovarian cancer: evidence, experience and clinical potential |
| Q49723005 | PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer |
| Q26798352 | PARP inhibitors in the management of breast cancer: current data and future prospects |
| Q44214997 | PARP inhibitors: pitfalls and promises |
| Q53682668 | PARP inhibitors: the journey from research hypothesis to clinical approval. |
| Q42356655 | PARP inhibitors: the race is on. |
| Q59812901 | PARP-1 regulates DNA repair factor availability |
| Q36287422 | PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients |
| Q35540013 | PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. |
| Q99238336 | Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity |
| Q38953629 | Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems |
| Q36941966 | Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer |
| Q92796852 | Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer |
| Q33415400 | Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses |
| Q33621410 | Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer |
| Q35895214 | Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. |
| Q28072204 | Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine |
| Q36855234 | Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years |
| Q90346203 | Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas |
| Q90425010 | Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10 |
| Q39454057 | Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review |
| Q64387026 | Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era |
| Q42673155 | Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials |
| Q38526322 | Role of PARP-1 in prostate cancer. |
| Q94487374 | Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial |
| Q104112905 | SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma |
| Q64979612 | Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. |
| Q48111447 | Sirtuins are Unaffected by PARP Inhibitors Containing Planar Nicotinamide Bioisosteres |
| Q57793601 | State-of-the-art strategies for targeting the DNA damage response in cancer |
| Q48129205 | Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. |
| Q48219721 | Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors. |
| Q93027996 | Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies |
| Q36104739 | Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. |
| Q89520945 | Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma |
| Q33607384 | Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. |
| Q38806371 | Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes |
| Q64058293 | Tailoring Ovarian Cancer Treatment: Implications of Mutations |
| Q100526333 | Targetable gene fusions and aberrations in genitourinary oncology |
| Q38760610 | Targeted agents and combinations in ovarian cancer: where are we now? |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q63359576 | Targeted therapy in ovarian cancer |
| Q26739923 | Targeting DNA Replication Stress for Cancer Therapy |
| Q60959613 | Targeting Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? |
| Q27022821 | Targeting the adaptive molecular landscape of castration-resistant prostate cancer |
| Q38212470 | Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects |
| Q38802077 | Targeting the hallmarks of ovarian cancer: The big picture |
| Q38601568 | Targeting tumor suppressor genes for cancer therapy |
| Q36921422 | The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin |
| Q33874466 | The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice |
| Q60045735 | The clinical promise of immunotherapy in triple-negative breast cancer |
| Q47278103 | The development of PARP as a successful target for cancer therapy |
| Q50098388 | The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer |
| Q38168060 | The genetic epidemiology of prostate cancer and its clinical implications |
| Q50187396 | The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells |
| Q89747982 | The kinase polypharmacology landscape of clinical PARP inhibitors |
| Q49352712 | The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities |
| Q27022113 | The promise of circulating tumor cell analysis in cancer management |
| Q50345037 | The rise of genomic profiling in ovarian cancer |
| Q53544515 | The sooner the better: Genetic testing following ovarian cancer diagnosis. |
| Q38683171 | Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities |
| Q91728273 | Therapeutic implications of germline genetic findings in cancer |
| Q39345771 | Treatment strategies for DNA repair-deficient prostate cancer |
| Q41955361 | Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status |
| Q26745673 | Trial watch - inhibiting PARP enzymes for anticancer therapy |
| Q92859213 | Triple-negative breast cancer: recent treatment advances |
| Q52592609 | Update on PARP Inhibitors in Breast Cancer. |
| Q28075761 | Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment |
| Q52587869 | Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. |
| Q28071541 | Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic |
| Q90394872 | Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer |
| Q50089515 | Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study |
| Q38777616 | What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? |
| Q57111690 | Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer? |
| Q41404014 | Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours |
| Q35676066 | YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors. |
Search more.